SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.26+1.2%Nov 11 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: zeta1961 who wrote (15849)2/22/2005 11:06:13 PM
From: Biomaven  Read Replies (1) of 52153
 
Thanks, Zeta - much appreciated.

This was particularly interesting:

Paclitaxel poliglumex also had schedule-independent synergy with therapeutic radiation (both single-dose and fractionated), with an extremely high enhancement factor of approximately 8 (Fig. 4). Unlike paclitaxel or docetaxel, paclitaxel poliglumex did not sensitize normal skin or gut tissue to radiation [25]. These striking findings are currently being explored in phase I-II clinical trials.

Of course from an investment perspective everything pales in comparison to the top-line findings due next month. I remain long, although I lightened up slightly in the recent pop.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News